Errata

Please note, these errata apply to High-Yield Urology 2023. Please email highyieldurology@gmail.com with any additional errors you identify in the book. Many thanks to those who have brought these errata to our attention.

31	Avelumab and Atezolizumab mechanisms should be listed as PD-L1, not PD-1
77	Tamm-Horsfall proteins are erroneously listed as promoters of stone formation and should be listed as inhibitors of stone formation

Please note, these errata apply to High-Yield Urology 2022.

Page	Erratum & Correction
7	"Pheos in RCC" should be corrected to "Pheos in VHL"
16	The mechanism of Axitinib is erroneously listed as "mAB" and should be corrected to "TKI" as it is a Tyrosine Kinase Inhibitor
26	Testing Pearl 6g - urine pH with ammonium challenge is erroneously listed as "> 6.8" and should be corrected to "< 6.8"
27 & 37	The middle rectal artery arises from the Anterior (not Posterior) Branch of the Internal Iliac
31	The following agents are listed in the table but do not currently have a role in Advanced UC management: Ipilimumab, Bevacizumab, Lenvatinib, Axitinib Avelumab and Atezolizumab mechanisms should be listed as PD-L1, not PD-1
53	"ANC > 15k" should be corrected to "ANC > 1.5k)
70	Complete distal RTA can cause hyperchloremic (not hypochloremic) metabolic acidosis
70	Tamm-Horsfall proteins are erroneously listed as promoters of stone formation and should be listed as inhibitors of stone formation
83	The diagnosis of IC/BPS is erroneously listed as requiring six "months" of symptoms and should be corrected to six "weeks"
126	"both patterns" should be corrected to "both partners"